Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression
- Cancer Cell. 2026 Jun 8;44(6):1179-1200.e14. doi: 10.1016/j.ccell.2026.03.015.
- 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
- 2. Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.
- 3. Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27705, USA.
- 4. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- 5. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
- 6. Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
- 7. Sutter Institute for Medical Research, Roseville, CA 95661, USA.
- 8. Institute for Precision Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA.
- 9. Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
- 10. Department of Surgery, Duke University School of Medicine, Durham, NC 27708, USA.
- 11. Department of Surgery, Washington University School of Medicine, St. Louis, MO 63108, USA.
- 12. Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Republic of Korea.
- 13. Institute for Precision Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA; UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
- 14. UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
- 15. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. Electronic address: [email protected].
Immune escape during the ductal carcinoma in situ (DCIS)-to-invasive breast Cancer (IBC) transition shapes tumor evolution. Through transcriptomic mapping of the immune landscapes of normal breast, DCIS, and IBC from large patient cohorts, we identified T and myeloid cells as the primary distinguishing features between DCIS and IBC. We discovered cycling regulatory T cells (cycTreg) as an orchestrator of immunosuppression in IBC. cycTreg frequency predicts cytotoxic CD8+, TCR diversity, disease-specific survival in IBC, and recurrence in DCIS. In a rat model of breast Cancer, we demonstrated that cycTreg act as precursors to mature Treg and are inducible by tumor-localized type 2 dendritic cells. Profiling of tumors subjected to αOX40 and αPD-L1 therapies revealed an IL-33-mediated fibroblast-cycTreg signaling loop, the disruption of which enhances intratumoral antigen-experienced CD8+ effectors and systemic immunosurveillance. Our study defines cycTreg as critical inducers of immune escape and promising immuno-oncology targets in breast Cancer.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
-
target: Interleukin RelatedResearch Areas: Inflammation/Immunology
-
Cat. No.Product NameCategory/Application